BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Intrinsic Value
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. [ Read More ]
The intrinsic value of one BCRX stock under the Base Case scenario is 12.9296 USD. Compared to the current market price of 5.3095 USD, BioCryst Pharmaceuticals Inc is Undervalued by 59%.
Valuation Backtest
BioCryst Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling BCRX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of BioCryst Pharmaceuticals Inc's business.
What risks and challenges
does BioCryst Pharmaceuticals Inc face in the near future?
Summarize the latest earnings report
of BioCryst Pharmaceuticals Inc.
Provide P/E
for BioCryst Pharmaceuticals Inc and its competitors.
Balance Sheet Decomposition
BioCryst Pharmaceuticals Inc
Current Assets | 496m |
Cash & Short-Term Investments | 389m |
Receivables | 57m |
Other Current Assets | 50m |
Non-Current Assets | 21m |
PP&E | 20.9m |
Other Non-Current Assets | 80k |
Current Liabilities | 150m |
Accounts Payable | 20.9m |
Accrued Liabilities | 103.9m |
Other Current Liabilities | 25.2m |
Non-Current Liabilities | 822.5m |
Long-Term Debt | 814.1m |
Other Non-Current Liabilities | 8.4m |
Earnings Waterfall
BioCryst Pharmaceuticals Inc
Revenue
|
331.4m
USD
|
Cost of Revenue
|
-4.7m
USD
|
Gross Profit
|
326.8m
USD
|
Operating Expenses
|
-428.9m
USD
|
Operating Income
|
-102.2m
USD
|
Other Expenses
|
-124.4m
USD
|
Net Income
|
-226.5m
USD
|
Free Cash Flow Analysis
BioCryst Pharmaceuticals Inc
What is Free Cash Flow?
BCRX Profitability Score
Profitability Due Diligence
BioCryst Pharmaceuticals Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
BioCryst Pharmaceuticals Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
BCRX Solvency Score
Solvency Due Diligence
BioCryst Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
BioCryst Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BCRX Price Targets Summary
BioCryst Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for BCRX is 14.0946 USD with a low forecast of 6.06 USD and a high forecast of 31.5 USD.
Ownership
BCRX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BCRX Price
BioCryst Pharmaceuticals Inc
Average Annual Return | 33.03% |
Standard Deviation of Annual Returns | 83.96% |
Max Drawdown | -83% |
Market Capitalization | 1.1B USD |
Shares Outstanding | 206 150 000 |
Percentage of Shares Shorted | 15.69% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The company is headquartered in Durham, North Carolina and currently employs 358 full-time employees. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The firm has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.
Contact
IPO
Employees
Officers
The intrinsic value of one BCRX stock under the Base Case scenario is 12.9296 USD.
Compared to the current market price of 5.3095 USD, BioCryst Pharmaceuticals Inc is Undervalued by 59%.